The Food and Drug Administration last week authorized the emergency use of a third diagnostic test that detects and differentiates flu and COVID-19 viruses from one another. 

The test from the Centers for Disease Control and Prevention, along with previously authorized tests from BioFire Diagnostics LLC and QIAGEN GmbH, require only a single sample from patients who exhibit respiratory disease symptoms. FDA said these tests will use fewer supplies and provide faster and comprehensive results.

Related News Articles

Headline
AHA’s The Value Initiative is providing new resources to support hospitals’ and health systems’ efforts to adopt team-based care for patients with an acute or…
Headline
A Lancet study published Sept. 25 indicates that few in the U.S. adult population formed antibodies against SARS-CoV-2, at least during the virus’ first wave…
Perspective
More than 200,000 of our friends, family members, fellow citizens and front-line workers have succumbed to COVID-19 since March. To put that in context, that’s…
Headline
The Food and Drug Administration last week reissued its emergency use authorization for the Abbott ID NOW COVID-19 test to indicate that the product is…
Headline
Proactive COVID-19 testing of all long-term care staff and residents, who are usually at higher risk of contracting the virus, may help prevent potential…
Headline
The Food and Drug Administration yesterday approved a new drug application for propofol injectable emulsion, an intravenous general anesthetic and sedation…